Hospital
Oroville Hospital
Oroville Hospital was paid $49.45M by Medicaid between Jan 2018 and Nov 2024, across 421 billing codes. Its largest line is 87635, Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe — 7.7% of everything it billed.
33Billing provider infoOROVILLE HOSPITAL
OROVILLE, CA 95966
OROVILLE, CA 95966
33aNPI1871606269assigned 08/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$49.45M
24GClaims2,529,303
24DCodes billed421
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#60 of 410
Median peer was paid$6.90M
This provider vs. median7.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DUNCAN, COLLEEN controls 16+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 268,181 | $4.61M | |
| 2019 | 338,527 | $4.88M | |
| 2020 | 337,586 | $4.92M | |
| 2021 | 358,405 | $7.61M | |
| 2022 | 371,492 | $8.46M | |
| 2023 | 448,203 | $9.81M | |
| 2024incomplete | 406,909 | $9.16M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 7.7% | 43,796 | 38,403 | $3.81M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4.4% | 84,649 | 84,072 | $2.20M |
| 80053 | Comprehensive metabolic panel | 4.4% | 202,152 | 191,279 | $2.16M |
| 84443 | Thyroid stimulating hormone (TSH) | 4.1% | 120,056 | 118,537 | $2.01M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.9% | 39,473 | 38,039 | $1.95M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.2% | 204,564 | 191,615 | $1.57M |
| 0450 | Emergency room services | 3.1% | 26,159 | 23,926 | $1.54M |
| 80061 | Lipid panel | 3.0% | 129,252 | 128,228 | $1.50M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.7% | 18,605 | 18,256 | $1.33M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.4% | 28,049 | 27,135 | $1.18M |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.3% | 118,484 | 117,572 | $1.15M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.8% | 6,620 | 6,473 | $884K |
409 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.8% | 5,695 | $877K |
| 82607 | 1.5% | 47,152 | $735K | |
| 93000 | 1.4% | 15,392 | $700K | |
| 0750 | 1.4% | 4,083 | $690K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.4% | 18,774 | $672K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.3% | 18,773 | $663K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 4,712 | $662K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.2% | 9,120 | $606K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 7,154 | $535K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 21,463 | $521K |
| 99199 | Unlisted special service, procedure or report | <1% | 7,482 | $476K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 2,661 | $459K |
| 80074 | <1% | 9,784 | $450K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 25,064 | $440K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 5,759 | $436K |
| 86481 | <1% | 6,959 | $430K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,692 | $413K |
| 82728 | <1% | 32,024 | $412K | |
| 82746 | <1% | 24,336 | $347K | |
| 84439 | <1% | 38,248 | $314K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,542 | $308K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 7,651 | $302K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,611 | $299K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 21,310 | $296K |
| 84466 | <1% | 24,965 | $292K | |
| 83735 | <1% | 40,247 | $288K | |
| 83013 | <1% | 4,435 | $273K | |
| 71250 | <1% | 2,315 | $268K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 8,770 | $258K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,184 | $252K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 8,837 | $250K |
| 86803 | <1% | 18,083 | $244K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,341 | $224K |
| 97750 | <1% | 4,587 | $223K | |
| 76770 | <1% | 3,883 | $221K | |
| 82043 | <1% | 36,899 | $221K | |
| 94060 | <1% | 4,534 | $214K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 5,818 | $214K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,284 | $210K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 3,360 | $210K |
| 84550 | <1% | 45,529 | $210K | |
| 84153 | <1% | 11,976 | $207K | |
| 84403 | <1% | 7,781 | $204K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 9,339 | $201K |
| 0361 | <1% | 1,175 | $195K | |
| 82550 | <1% | 25,357 | $195K | |
| 83880 | <1% | 6,779 | $194K | |
| 86780 | <1% | 17,869 | $189K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 25,530 | $184K |
| 87631 | <1% | 2,808 | $180K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,003 | $177K |
| 76830 | Ultrasound, transvaginal | <1% | 3,414 | $174K |
| 71045 | Radiologic examination, chest; single view | <1% | 18,554 | $173K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,723 | $170K |
| 83615 | <1% | 24,418 | $166K | |
| 0360 | <1% | 965 | $162K | |
| 83540 | <1% | 26,702 | $161K | |
| 94729 | <1% | 4,381 | $156K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 273 | $150K |
| 97139 | <1% | 4,276 | $146K | |
| 81001 | <1% | 44,903 | $138K | |
| 87536 | <1% | 1,768 | $138K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 965 | $136K |
| 84100 | <1% | 28,320 | $136K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,507 | $133K |
| 86255 | <1% | 11,934 | $129K | |
| 94618 | <1% | 3,158 | $127K | |
| 86140 | <1% | 23,674 | $127K | |
| 83970 | <1% | 3,471 | $126K | |
| 82670 | <1% | 4,088 | $125K | |
| 87340 | <1% | 11,157 | $118K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,003 | $115K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,866 | $114K |
| 84484 | <1% | 8,404 | $113K | |
| 94727 | <1% | 4,396 | $113K | |
| 83525 | <1% | 9,017 | $111K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 740 | $111K |
| 0762 | <1% | 846 | $106K | |
| 84481 | <1% | 7,235 | $105K | |
| 85027 | <1% | 17,960 | $103K | |
| 83605 | <1% | 6,264 | $98K | |
| 82570 | <1% | 21,517 | $97K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 3,422 | $97K |
| 93015 | <1% | 612 | $96K | |
| 73030 | <1% | 4,948 | $95K | |
| 83001 | <1% | 4,681 | $92K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 892 | $91K |
| 87077 | <1% | 13,333 | $88K | |
| 86431 | <1% | 14,593 | $86K | |
| 73630 | <1% | 4,680 | $84K | |
| 87070 | <1% | 9,175 | $84K | |
| 93224 | <1% | 478 | $84K | |
| 59025 | Fetal non-stress test | <1% | 3,009 | $83K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 285 | $82K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,752 | $82K |
| 72110 | <1% | 2,387 | $81K | |
| 73562 | <1% | 4,636 | $81K | |
| 76536 | <1% | 1,736 | $80K | |
| 81513 | <1% | 696 | $79K | |
| 83002 | <1% | 3,918 | $77K | |
| 76801 | <1% | 1,635 | $75K | |
| 82274 | <1% | 6,798 | $75K | |
| 87186 | <1% | 8,269 | $71K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,531 | $71K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,607 | $69K |
| 72114 | <1% | 1,478 | $68K | |
| 85730 | <1% | 10,110 | $67K | |
| 87040 | <1% | 3,286 | $63K | |
| 87088 | <1% | 9,344 | $63K | |
| 83690 | <1% | 8,227 | $62K | |
| 85610 | <1% | 15,191 | $61K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,925 | $60K |
| 86762 | <1% | 4,698 | $60K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,962 | $60K |
| 97010 | <1% | 1,651 | $59K | |
| 73610 | <1% | 2,873 | $59K | |
| 74178 | <1% | 309 | $59K | |
| 0720 | <1% | 1,464 | $56K | |
| 84154 | <1% | 3,263 | $56K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,335 | $55K |
| 70486 | <1% | 378 | $53K | |
| 73130 | <1% | 2,528 | $53K | |
| 71271 | <1% | 633 | $50K | |
| 85651 | <1% | 17,406 | $47K | |
| 74018 | <1% | 3,575 | $47K | |
| 84146 | <1% | 2,460 | $46K | |
| 81003 | <1% | 18,594 | $45K | |
| 73110 | <1% | 2,001 | $45K | |
| 82652 | <1% | 1,265 | $41K | |
| 96367 | <1% | 560 | $40K | |
| 72070 | <1% | 1,815 | $40K | |
| 72100 | <1% | 1,493 | $40K | |
| 84460 | <1% | 7,773 | $39K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,484 | $39K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 4,689 | $38K |
| 84450 | <1% | 7,410 | $37K | |
| 84166 | <1% | 2,455 | $35K | |
| 0710 | <1% | 1,219 | $35K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,274 | $35K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 9,701 | $35K |
| 73502 | <1% | 1,386 | $34K | |
| 83014 | <1% | 4,442 | $33K | |
| 87209 | <1% | 2,208 | $32K | |
| 84436 | <1% | 4,677 | $32K | |
| 86706 | <1% | 3,443 | $32K | |
| 72141 | <1% | 97 | $31K | |
| 73221 | <1% | 109 | $31K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,935 | $31K |
| 76641 | <1% | 676 | $31K | |
| 87522 | Neg quan hep c or qual rna | <1% | 815 | $31K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,057 | $30K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 332 | $30K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,152 | $30K |
| 84702 | <1% | 2,331 | $30K | |
| 93971 | <1% | 275 | $30K | |
| 95806 | <1% | 125 | $29K | |
| 80069 | <1% | 3,954 | $29K | |
| 86317 | <1% | 2,126 | $28K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 172 | $28K |
| G0378 | Hospital observation service, per hour | <1% | 975 | $28K |
| 93880 | <1% | 201 | $27K | |
| 84144 | <1% | 1,266 | $27K | |
| 86039 | <1% | 2,392 | $26K | |
| 82105 | <1% | 1,831 | $26K | |
| 72050 | <1% | 792 | $26K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 392 | $25K |
| 76642 | <1% | 481 | $25K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 595 | $25K |
| 85007 | <1% | 9,507 | $25K | |
| 86141 | <1% | 2,428 | $24K | |
| 87205 | <1% | 6,019 | $24K | |
| 87390 | <1% | 1,198 | $24K | |
| 86160 | <1% | 1,369 | $23K | |
| 84480 | <1% | 1,598 | $23K | |
| 80076 | <1% | 3,342 | $23K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 709 | $23K |
| 84479 | <1% | 3,495 | $22K | |
| 82247 | <1% | 4,192 | $22K | |
| 95811 | <1% | 29 | $22K | |
| 80055 | <1% | 537 | $21K | |
| 80164 | <1% | 1,750 | $21K | |
| 82947 | <1% | 4,991 | $21K | |
| 87481 | <1% | 644 | $20K | |
| 72131 | <1% | 106 | $20K | |
| 87081 | <1% | 2,771 | $20K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,264 | $20K |
| 86480 | <1% | 537 | $20K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 416 | $19K |
| 87045 | <1% | 1,979 | $19K | |
| 82040 | <1% | 3,109 | $19K | |
| 82310 | <1% | 3,632 | $18K | |
| 86703 | <1% | 1,201 | $17K | |
| 92526 | <1% | 288 | $17K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,452 | $17K |
| 84075 | <1% | 2,871 | $17K | |
| 87177 | <1% | 1,863 | $17K | |
| 86704 | <1% | 1,365 | $17K | |
| 88313 | <1% | 1,598 | $17K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,068 | $16K |
| 82950 | <1% | 3,714 | $16K | |
| 85652 | <1% | 5,987 | $16K | |
| 85379 | <1% | 1,415 | $16K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,269 | $16K |
| 77080 | <1% | 725 | $16K | |
| 88304 | <1% | 822 | $16K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 77 | $16K |
| 81025 | <1% | 3,001 | $15K | |
| 82150 | <1% | 2,348 | $15K | |
| 82077 | <1% | 1,071 | $15K | |
| 82565 | <1% | 3,172 | $15K | |
| 84295 | <1% | 3,596 | $15K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 507 | $14K |
| 84132 | <1% | 3,164 | $14K | |
| 52000 | <1% | 372 | $14K | |
| 73560 | <1% | 724 | $14K | |
| 82435 | <1% | 2,962 | $14K | |
| 86708 | <1% | 1,240 | $14K | |
| 84520 | <1% | 3,640 | $13K | |
| 88342 | <1% | 831 | $13K | |
| 88312 | <1% | 1,397 | $13K | |
| V5008 | Hearing screening | <1% | 427 | $13K |
| 82374 | <1% | 2,968 | $13K | |
| 72040 | <1% | 453 | $13K | |
| 82533 | <1% | 802 | $13K | |
| 84155 | <1% | 3,467 | $12K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 49 | $12K |
| 95819 | <1% | 194 | $12K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 149 | $12K |
| 64493 | <1% | 166 | $12K | |
| 82951 | <1% | 940 | $12K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 12 | $11K |
| 82784 | <1% | 801 | $11K | |
| 73080 | <1% | 383 | $11K | |
| 86850 | <1% | 2,641 | $11K | |
| 93017 | <1% | 273 | $10K | |
| 93350 | <1% | 110 | $10K | |
| 83090 | <1% | 834 | $10K | |
| 97165 | <1% | 180 | $10K | |
| 76870 | <1% | 244 | $10K | |
| 80178 | <1% | 1,584 | $10K | |
| 93970 | <1% | 44 | $9K | |
| 82248 | <1% | 1,990 | $9K | |
| 87449 | <1% | 1,134 | $9K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,743 | $9K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,564 | $9K |
| 93270 | <1% | 168 | $9K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,725 | $9K |
| 82977 | <1% | 1,290 | $8K | |
| 86592 | <1% | 2,113 | $8K | |
| 86900 | <1% | 2,086 | $8K | |
| 86665 | <1% | 246 | $8K | |
| 86901 | <1% | 2,075 | $8K | |
| 96415 | <1% | 465 | $8K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,061 | $7K |
| 86787 | <1% | 594 | $7K | |
| 86705 | <1% | 577 | $7K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 893 | $7K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 54 | $7K |
| 84703 | <1% | 1,032 | $7K | |
| 73523 | <1% | 175 | $7K | |
| 0510 | <1% | 279 | $7K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,164 | $7K |
| 95886 | <1% | 113 | $6K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 85 | $6K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,923 | $6K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,221 | $6K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 900 | $6K |
| 84165 | <1% | 712 | $6K | |
| 73140 | <1% | 322 | $6K | |
| 87147 | <1% | 1,401 | $6K | |
| 92522 | <1% | 36 | $6K | |
| 87106 | <1% | 598 | $6K | |
| 87899 | <1% | 976 | $5K | |
| 87075 | <1% | 590 | $5K | |
| 87328 | <1% | 560 | $5K | |
| 99070 | <1% | 401 | $5K | |
| 84156 | <1% | 1,788 | $5K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,052 | $5K |
| 94250 | <1% | 1,067 | $5K | |
| 82140 | <1% | 388 | $5K | |
| 82378 | <1% | 233 | $5K | |
| 87493 | <1% | 178 | $5K | |
| 73090 | <1% | 153 | $5K | |
| 77066 | Tomosynthesis, mammo | <1% | 39 | $5K |
| 87430 | <1% | 410 | $5K | |
| 87329 | <1% | 559 | $4K | |
| 88341 | <1% | 37 | $4K | |
| 72052 | <1% | 78 | $4K | |
| 88104 | <1% | 145 | $4K | |
| 86664 | <1% | 243 | $4K | |
| 64483 | <1% | 121 | $4K | |
| 86765 | <1% | 363 | $4K | |
| 72128 | <1% | 12 | $3K | |
| 86663 | <1% | 243 | $3K | |
| 85045 | <1% | 878 | $3K | |
| 31624 | <1% | 189 | $3K | |
| 86735 | <1% | 324 | $3K | |
| 86308 | <1% | 614 | $3K | |
| 87324 | <1% | 392 | $3K | |
| G0299 | Direct skilled nursing services of a registered nurse (rn) in the home health or hospice setting, each 15 minutes | <1% | 56 | $3K |
| 86769 | <1% | 90 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 48 | $3K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 18 | $3K |
| 64494 | <1% | 92 | $3K | |
| 97130 | <1% | 98 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,331 | $3K |
| 93325 | <1% | 27 | $2K | |
| 93018 | <1% | 203 | $2K | |
| 81002 | <1% | 727 | $2K | |
| 97799 | <1% | 55 | $2K | |
| 87420 | <1% | 377 | $2K | |
| 97129 | <1% | 98 | $2K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 28 | $2K |
| 94010 | <1% | 161 | $2K | |
| 73590 | <1% | 74 | $2K | |
| 94760 | <1% | 228 | $2K | |
| 0272 | <1% | 191 | $2K | |
| 96417 | <1% | 89 | $2K | |
| 86334 | <1% | 116 | $2K | |
| 73120 | <1% | 78 | $2K | |
| 87116 | <1% | 154 | $2K | |
| 86593 | <1% | 381 | $2K | |
| 82553 | <1% | 115 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 595 | $2K |
| 87206 | <1% | 196 | $1K | |
| 85018 | <1% | 582 | $1K | |
| 87101 | <1% | 154 | $1K | |
| 82952 | <1% | 352 | $1K | |
| 88108 | <1% | 214 | $1K | |
| 73620 | <1% | 53 | $1K | |
| 87015 | <1% | 154 | $1K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 101 | $1K |
| 86677 | <1% | 79 | $1K | |
| 73100 | <1% | 38 | $785.72 | |
| 52648 | <1% | 29 | $744.00 | |
| 95909 | <1% | 12 | $731.62 | |
| 97116 | <1% | 67 | $712.02 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 344 | $672.99 |
| 87338 | <1% | 51 | $639.50 | |
| 82330 | <1% | 43 | $638.64 | |
| 99152 | <1% | 20 | $602.29 | |
| 74022 | <1% | 14 | $595.16 | |
| 81050 | <1% | 263 | $533.53 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 233 | $524.49 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 94 | $447.34 |
| 74019 | <1% | 18 | $422.36 | |
| 73060 | <1% | 13 | $415.74 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 34 | $397.78 |
| 82465 | <1% | 109 | $396.40 | |
| G0162 | Skilled services by a registered nurse (rn) for management and evaluation of the plan of care; each 15 minutes (the patient's underlying condition or complication requires an rn to ensure that essential non-skilled care achieves its purpose in the home health or hospice setting) | <1% | 13 | $386.44 |
| 82805 | <1% | 15 | $383.48 | |
| 90714 | <1% | 12 | $371.56 | |
| 73600 | <1% | 12 | $351.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 76 | $272.25 |
| 84145 | <1% | 12 | $266.09 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 117 | $248.00 |
| 84432 | <1% | 18 | $236.01 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 24 | $233.88 |
| 70220 | <1% | 15 | $233.16 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | <1% | 91 | $213.25 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 34 | $211.91 |
| 86709 | <1% | 24 | $209.02 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 78 | $207.34 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 204 | $182.42 |
| 27096 | <1% | 13 | $172.96 | |
| 84478 | <1% | 37 | $172.35 | |
| 43248 | <1% | 25 | $170.06 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 44 | $158.48 |
| 82010 | <1% | 13 | $135.42 | |
| 87184 | <1% | 32 | $133.46 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 25 | $123.68 |
| 87425 | <1% | 12 | $106.32 | |
| 87210 | <1% | 39 | $98.25 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 12 | $95.91 |
| 71101 | <1% | 12 | $93.06 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 15 | $67.35 |
| 84300 | <1% | 13 | $50.89 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 18 | $50.20 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 151 | $32.65 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 241 | $13.78 |
| 0272R | 0% | 630 | $0.00 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 0% | 3,749 | $0.00 |
| 0270R | 0% | 752 | $0.00 | |
| 99173 | 0% | 71 | $0.00 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 459 | $0.00 |
| 0370R | 0% | 152 | $0.00 | |
| 99204 | Doctor's office visit, new patient (more involved) | 0% | 148 | $0.00 |
| 99203 | Doctor's office visit, new patient (routine) | 0% | 226 | $0.00 |
| 77062 | 0% | 12 | $0.00 | |
| 0710R | 0% | 58 | $0.00 | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 0% | 23 | $0.00 |
| 90734 | 0% | 12 | $0.00 | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 0% | 12 | $0.00 |
| 90715 | 0% | 15 | $0.00 | |
| 0002A | 0% | 18 | $0.00 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | 0% | 29 | $0.00 |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 0% | 20 | $0.00 |
| 99201 | 0% | 12 | $0.00 | |
| 0250R | 0% | 584 | $0.00 | |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 10,637 | $0.00 |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 2,393 | $0.00 |
| 90688 | 0% | 31 | $0.00 | |
| 0271R | 0% | 137 | $0.00 | |
| 0259R | 0% | 24 | $0.00 | |
| 90651 | 0% | 12 | $0.00 | |
| 90686 | 0% | 14 | $0.00 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 13 | $0.00 |
| 92551 | 0% | 20 | $0.00 | |
| 0001A | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDUNCAN, COLLEEN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Oroville Hospital | Oroville, CA | $19.52M |
| Oroville Hospital | Oroville, CA | $17.36M |
| Orohealth Corporation a Non Profit Healthcare System | Oroville, CA | $10.65M |
| Oroville Hospital | Oroville, CA | $6.03M |
| Oroville Hospital | Oroville, CA | $5.44M |
| Oroville Hospital | Oroville, CA | $644K |
| Oroville Hospital | Oroville, CA | $110K |
| Oroville Hospital | Oroville, CA | $49K |
| Oroville Hospital | Oroville, CA | $15K |
| Oroville Hospital | Oroville, CA | $11K |
| Oroville Hospital | Oroville, CA | $11K |
| Oroville Hospital | Oroville, CA | $10K |
| Oroville Hospital | Oroville, CA | $8K |
| Oroville Hospital | Oroville, CA | $75.60 |
| Oroville Hospital | Oroville, CA | $0.00 |
| Oroville Hospital | Oroville, CA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.